California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
MENLO PARK, Calif., Sept. 28, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in October.
| Event: | Cell & Gene Meeting on the Mesa | ||
| Date: | October 5, 2017 | ||
| Time: | 2:15 – 2:30 p.m. PT | ||
| Location: | La Jolla, CA | ||
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
| Event: | Chardan Gene Therapy Conference | ||
| Date: | October 10, 2017 | ||
| Time: | 2:00 – 2:25 p.m. ET | ||
| Location: | New York, NY | ||
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | ||
| Event: | Jefferies Gene Technology Summit Conference | ||
| Date: | October 12, 2017 | ||
| Location: | New York, NY | ||
| Panel: | Mehdi Gasmi, Ph.D., chief science and technology officer |
A live and replay video webcast of the Cell & Gene Meeting on the Mesa may be accessed by visiting www.meetingonthemesa.com/webcast/.
A live and replay audio webcast of the Chardan Gene Therapy Conference fireside chat will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact: Charles Butler Vice President, Investor Relations & Corporate Communications 650-272-6260 [email protected]
